Top Markets
#1 GEKKO GEKKO +51.79%
#2 ADO Protocol ADO Protocol +38.49%
#3 Helium Helium +33.05%
#4 Pons Pons +29.98%
#5 TENDIES TENDIES +21.40%
#6 龙虾 (Lobster) 龙虾 (Lobster) +20.56%
#7 o1.exchange o1.exchange +18.98%
#8 Giggle Fund Giggle Fund +18.51%
#9 Main Street Yield Main Street Yield +17.48%
#10 CZ'S Dog CZ'S Dog +16.11%
Coin of the day
GEKKO GEKKO
Settings
Language
ENGLISH
Currency
USD
Theme
Kolon TissueGene, Inc. Kolon TissueGene, Inc.

Kolon TissueGene, Inc.

950160
Rank in Stocks #9085
Kolon TissueGene, Inc. is a biopharmaceutical firm specializing in the... Kolon TissueGene, Inc. is a biopharmaceutical firm specializing in the advancement of clinical-stage cell-based treatments for osteoarthritis. Its flagship offering is TG-C, a proprietary platform technology that integrates allogeneic primary cells with genetically engineered counterparts. Established by Kwan H. Lee on June 9, 1999, the enterprise maintains its corporate headquarters in Rockville, Maryland.
Share Price
$12.94
Last synced: 2026-08-28
Market Cap
$1.10B
Change (1 day)
-0.16%
Change (1 year)
-51.50%
Country
US
Trade Kolon TissueGene, Inc. (950160)

Category

Healthcare
P/E ratio for Kolon TissueGene, Inc. (950160)
P/E ratio as of 2026 TTM: 0
According to Kolon TissueGene, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Kolon TissueGene, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.